Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stomach ultrasound may guide safer anesthesia for opioid users

NCT ID NCT07537582

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether using a stomach ultrasound before sedation can help anesthesiologists make safer decisions for chronic pain patients. These patients often take opioids or have other conditions that slow stomach emptying, raising the risk of food or liquid entering the lungs during sedation. The study will track how often the ultrasound changes the planned anesthesia approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that gastric ultrasound helps anesthesiologists make safer decisions for chronic pain patients, potentially reducing rare but serious complications.
What could go wrong
This is an observational study, not a treatment trial. It only measures whether ultrasound changes decisions, not whether it actually prevents harm. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This will be a single-center, prospective observational cohort study conducted at Danat Al Emarat Hospital, Abu Dhabi, UAE. Adult patients scheduled for elective chronic pain interventional procedures under procedural sedation will be screened for eligibility.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients were eligible for inclusion if they met all of the following criteria: * Age ≥18 years * Scheduled for elective chronic pain interventional procedures under procedural sedation * Adherence to standard preoperative fasting guidelines (≥6 hours for clear fluids and ≥8 hours for solids) * Presence of at least one clinical factor associated with delayed gastric emptying or increased risk of pulmonary aspiration, including: * Chronic opioid use (≥2 weeks) * Acute opioid administration within 24 hours prior to the procedure * Poorly controlled acute-on-chronic pain * Diabetes mellitus without established autonomic neuropathy * Symptoms of gastroesophageal reflux * Reduced functional mobility * ASA physical status II-III Exclusion Criteria: Patients will be excluded if any of the following present: * Age \<18 years * Previous gastric or esophageal surgery * Known pregnancy * Known hiatal hernia * Severe neurological disorders affecting swallowing or gastric motility * Established autonomic neuropathy affecting gastric emptying (e.g. advanced diabetic gastroparesis) * Morbid obesity (body mass index ≥35 kg·m-²), due to known limitations in gastric ultrasound image acquisition and reduced validity of volume estimation models * Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute opioid administration within 24 hours prior to the procedure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Danat Al Emarat Women & Children Hospital

    Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.